

VERTEX PHARMA - Time to Book Profits

<https://marketpublishers.com/r/V69B1DB0917EN.html>

Date: June 2012

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: V69B1DB0917EN

Abstracts

Vertex (VRTX) has evolved from an innovator to a profitable Biotech but at the current price the risk reward is well balanced. Positive read out of KALYDECO/VX-809 (CF potentiator/ CF corrector) combination in homozygous del508 mutation cystic fibrosis (CF) pts from PhIIb (data expected in mid-12) and PhIII trial, and other pipeline drugs can take the stock to new high, but failure along with disappointment in future sales of INCIVEK (HCV, telaprevir, L) could have major impact! Though we have positive expectations from KALYDECO/VX-809 in subpopulation, we expect the stock to remain volatile in the next one year due to CF related milestones, INCIVEK sales, and news from highly competitive HCV drugs pipeline.....For more detail, please read our report released on 11th June, 2012 on Vertex titled "Time to Book Profits....!"

Contents

COMPANIES MENTIONED

Vertex Pharma

I would like to order

Product name: VERTEX PHARMA - Time to Book Profits

Product link: <https://marketpublishers.com/r/V69B1DB0917EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V69B1DB0917EN.html>